Funding profile · Urology devices

UroDev Medical

Three Form D filings, $4.92 million sold, and $5.27 million in federal awards. No Regulation D filing has been made since May 2018, and no product ever reached the market.

$4.92MTotal sold across all three Form D filings
$5.27MFederal awards on record, NIH and Department of Defense
$13MTotal raised as stated by the CEO in February 2021, company-reported
0Form D filings since May 22, 2018

Data as of September 24, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Oct 2015 Indiegogo campaign $50,000 goal reached Public backers Independent
Dec 2015 PrimeUC competition $150,000 University of California PrimeUC Independent
Dec 2016 to Sep 2017 Equity, Rule 506(b) $2,928,731 of $5,239,995 38 Form D
Mar to May 2018 Equity, Rule 506(b) $1,996,108 of $2,000,000 29 Form D and D/A
2016 to 2024 Federal, non dilutive $5,267,071 NIH NIDDK; Defense Health Agency NIH, USAspending
By Feb 2021 Cumulative, as stated About $13M, of which $8M equity Not named Company-stated
2021 Series B, planned $10M to $15M target None announced No filing

What the filings show

Spinal Singularity, Inc. · Form D · filed Sep 27, 2017

First sale
Dec 15, 2016
Offered
$5,239,995 equity
Sold
$2,928,731 · $2,311,264 remaining
Investors
38 · average about $77,000
Exemption
Rule 506(b)
Related persons
Derek Herrera and Bill Colone (executive officers, directors); Christopher Jennings and Kenneth Baker (directors)
Filing
SEC EDGAR, CIK 0001717150

Spinal Singularity, Inc. · Form D · filed Apr 2, 2018

First sale
Mar 19, 2018
Offered
$2,000,000 equity
Sold
$907,756 · $1,092,244 remaining
Investors
6 · average about $151,000
Exemption
Rule 506(b)
Related persons
Herrera and Colone (executive officers, directors); Kenneth Baker, Andrew Gilbert and David Kaysen (directors)
Filing
SEC EDGAR, CIK 0001717150

Spinal Singularity, Inc. · Form D/A · filed May 22, 2018

First sale
Mar 19, 2018
Sold
$1,996,108 · $3,892 remaining
Investors
29 · average about $69,000
Related persons
The same five as the April filing
Filing
SEC EDGAR, CIK 0001717150

Reading the filings

  1. The first notice was 286 days late.Regulation D requires a Form D within 15 days of the first sale. First sale Dec 15, 2016; filed Sep 27, 2017. That is a housekeeping signal, not a valuation signal.
  2. The 2016 round closed at 56 percent.$2,928,731 of $5,239,995 offered, leaving $2,311,264 unsold. No amendment was filed, so on the record the offering simply stopped.
  3. The 2018 round shows a lead, then a sweep.April: 6 investors, $907,756, about $151,000 each. Seven weeks later: 29 investors, $1,996,108, about $69,000 each. The count rose almost fivefold while the average cheque fell by more than half, and the round closed within $3,892 of target.
  4. The filings cover about 62 percent of the stated equity.Form D sales total $4,924,839 against the roughly $8 million of equity claimed in February 2021, a gap of about $3.1 million spanning 2019 to 2021. Issuers raising under Section 4(a)(2) file no Form D, so the gap is unverified rather than improper.
  5. Government money exceeded venture money.Federal awards total $5,267,071, above the $4,924,839 of disclosed equity. The largest single sum was a Department of Defense grant of $3,553,457.21 in July 2019. The planned Series B never produced a filing.

Commercial signals

Signal Detail Source type
Regulatory No 510(k) and no PMA for either corporate name. Releases from 2018 to 2023 label the product an investigational device. Public record
Revenue All three filings answer the revenue range question “Decline to Disclose”. No product was authorised for sale. Public record
Clinical Pivotal study NCT05330598 enrolled 26 and terminated with a completion date of Feb 1, 2024. Reason: “Sponsor decision”. No results posted. Public record
Grant runway The Department of Defense award ran to Jun 30, 2024, record last modified Sep 16, 2024. Public record
Web presence Captures of urodevmedical.com return 200 through Mar 7, 2024 and 404 from Mar 19, 2024. The March 2026 capture is an advertising redirect page. Public record

What to watch

  • Any new Form D under either corporate name.
  • Assignment records for the patent estate, which would show where the technology went.
  • Results posting for NCT05330598.
  • Bright Uro, founded by the same founder in 2021, which reported an oversubscribed seed round of six million dollars in 2022.

The UroDev Medical story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Volt Health: Also in Medical Devices. A wearable electrostimulation device pitched at Y Combinator in 2017 to treat incontinence
  • Zenflow: Also in Medical Devices. A small nitinol coil that props open the prostatic urethra, delivered through a flexible scope and removable at any time
  • Vena Medical: Also in Medical Devices. A sub-millimetre camera that looks forward from inside a brain artery, and a balloon catheter built to pull a clot out on the first try
  • Corveus Medical: Also in Medical Devices. A Houston company building a catheter that deactivates one sympathetic nerve to relieve congestion in heart failure

Sources

  1. Public recordForm D, accession 0001717150-17-000001SEC · Sep 27, 2017
  2. Public recordForm D, accession 0001717150-18-000001SEC · Apr 2, 2018
  3. Public recordForm D/A, accession 0001717150-18-000002SEC · May 22, 2018
  4. Public recordFederal award W81XWH1910370, Defense Health AgencyUSAspending.gov
  5. Public recordAwards R43DK109865 and R44DK109865NIH RePORTER
  6. Public recordRegistry entries and posted results, five studiesClinicalTrials.gov
  7. Public record510(k), PMA, registration and device event searchesopenFDA · Sep 24, 2026
  8. Public recordCapture history for urodevmedical.comInternet Archive
  9. IndependentUroDev Medical Relocates to Minnesota From CaliforniaTwin Cities Business · Feb 3, 2021
  10. IndependentVeteran founded medical devices firm will bring its smart catheter to market in EdinaMinneapolis / St. Paul Business Journal · Feb 2, 2021
  11. IndependentSpinal Singularity Wins at First PrimeUC CompetitionMedTech Innovator · Dec 4, 2015
  12. InterviewDerek Herrera, CEO, Bright Uro: Changing the Standard of CareDocWire News · Aug 11, 2022
  13. CompanyUroDev Medical Appoints Dean Briesemeister as CEOPR Newswire · Apr 5, 2023

Compiled from SEC, NIH, USAspending, FDA and ClinicalTrials.gov public records and published reports as of September 24, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in UroDev Medical. This page is not an offer to sell or a recommendation to buy any security.